Application and Development of antiarrhythmic drugs in sudden cardiac death related diseases
LIN Chun-Jin, ZHENG Wei-Ping, LI Feng, JIANG Yun, XIAO Jian-Min, LIN Kai-Yang
（Provincial Clinical Medical College of Fujian Medical University，Emergency Center of Fujian Province，Department of Electrocardiogram，Fujian Provincial Hospital，Fuzhou Fujian 350001，China）
Abstract：Sudden cardiac death (SCD) is a serious complication of cardiovascular disease.Primary inherited arrhythmia syndrome and acute coronary syndrome are the two major causes of SCD .Antiarrhythmic drugs have been used in clinical application for nearly a hundred years. Both in the rescue and subsequent treatment and prevention of SCD related diseases,the antiarrhythmic drugs are still the basic treatment measures. With the development of evidencebased medicine, antiarrhythmic drugs have been changed in indications and instructions. Meanwhile research and development and application of new antiarrhythmic drugs in this area have brought new directions and focuses. This article describes the application and progress of the antiarrhythmic drugs for the SCD diseases.
林春锦, 郑炜平, 李峰, 江芸, 肖建敏, 林开阳. 心脏性猝死相关疾病抗心律失常药物的应用与进展[J]. 实用心电学杂志, 2015, 24(6): 391-397.
LIN Chun-Jin, ZHENG Wei-Ping, LI Feng, JIANG Yun, XIAO Jian-Min, LIN Kai-Yang. Application and Development of antiarrhythmic drugs in sudden cardiac death related diseases. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2015, 24(6): 391-397.
[1] Zipes DP，Camm AJ，Borggrefe M，et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention ofsudden cardiac deathexecutive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society ofCardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and thePrevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Eur Heart J，2006，27(17):20[KG-*5]99-2140.[2] 中华心血管病杂志编辑委员会心律失常循证工作组.遗传性原发性心律失常综合征诊断与治疗中国专家共识[J].中华心血管病杂志，2015，43(1):5-21.[3] Vaughan Williams EM.A classification of antiarrhythmic actions reassessed after a decade of new drugs[J].J Clin Pharmacol，1984，24(4):129-147.[4] 郭继鸿.胺碘酮的现代观点[J].临床心电学杂志，2007，16(2):143-151.[5] The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms.Task Force of theWorking Group on Arrhythmias of the European Society of Cardiology[J]. Circulation，1991，84(4):1831-1851.[6] Kodama I，Ogawa S，Inoue H，et al.Profiles of aprindine,cibenzoline,pilsicainide and pirmenol in the framework of the Sicilian Gambit.The GuidelineCommittee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology)[J].Jpn Circ J，1999，63(1):1-12.[7] Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. TheCardiac Arrhythmia Suppression Trial (CAST) Investigators[J].N Engl J Med，1989，321(6):406-412.[8] Echt DS，Liebson PR，Mitchell LB，et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac ArrhythmiaSuppression Trial[J].N Engl J Med，1991，324(12):781-788.[9] Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.The Cardiac Arrhythmia Suppression Trial II Investigators[J].N EnglJ Med，1992，327(4):2[KG-*5]27-233.[10] O′Gara PT，Kushner FG，Ascheim DD，et al. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: executive summary: areport of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation，2013，127(4):529-555.[11] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2015，43(5):380-393.[12] Priori SG，Wilde AA，Horie M，et al.HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primaryarrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013[J].Heart Rhythm，2013，10(12):1932-1963.[13] Pedersen CT，Kay GN，Kalman J，et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias[J]. Heart Rhythm，2014，11(10):e166-196.[14] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42(2):98-122.[15] Hjalmarson A，Fagerberg B.MERITHF mortality and morbidity data[J].Basic Res Cardiol，2000，95 Suppl 1:I 98-103.[16] Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS1.First International Study of InfarctSurvival Collaborative Group[J].Lancet，1986，2(8498):57-66.[17] Roberts R，Rogers WJ，Mueller HS，et al.Immediate versus deferred betablockade following thrombolytic therapy in patients with acute myocardialinfarction.Results of the Thrombolysis in Myocardial Infarction (TIMI) IIB Study[J]. Circulation，1991，83(2):422-437.[18] Pfisterer M，Cox JL，Granger CB，et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTOI experience.Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries[J]. J Am Coll Cardiol，1998，32(3):634-640.[19] Chen ZM，Pan HC，Chen YP，et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial[J].Lancet，2005，366(9497):1622-1632.[20] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J].中华心血管病杂志，2009，37(3):195-209.[21] 黄从新.Ⅲ类抗心律失常药物研究进展[J].中国实用内科杂志，2006，26(16):1279-1280.[22] Cairns JA，Connolly SJ，Roberts R，et al. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial(CAMIAT): rationale and protocol. CAMIATInvestigators[J].Am J Cardiol，1993，72(16):87F-94F.[23] Malik M，Camm AJ，Janse MJ，et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatmentwith amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)[J].J Am Coll Cardiol，2000，35(5):1263-1275.[24] 雷招宝.抗心律失常新药决奈达隆的不良反应与相互作用[J].中国新药杂志，2012，21(15):1826-1830.[25] Dickstein K，Vardas PE，Auricchio A，et al.2010 focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy.Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association[J]. Eur Heart J，2010，31(21):2677-2687.[26] Fuster V，Rydén LE，Cannom DS，et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patientswith atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation，2011，123(10):e269-367.[27] Coons JC，Plauger KM，Seybert AL，et al.Worsening heart failure in the setting of dronedarone initiation[J]. Ann Pharmacother，2010，44(9):1496-1500.[28] 陈刚，侯炳波，姚焰，等.维拉帕米敏感性束支内折返性室性心动过速的临床特点[J].中华心律失常学杂志，2014，18(6):454-457.[29] Nam GB，Kim YH，Antzelevitch C.Augmentation of J waves and electrical storms in patients with early repolarization[J].N Engl J Med，2008，358(19):2078-2079.[30] Tikkanen JT，Anttonen O，Junttila MJ，et al. Longterm outcome associated with early repolarization on electrocardiography[J].N Engl J Med，2009，361(26):2529-2537.[31] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.抗心律失常药物治疗建议[J].中华心血管病杂志，2001，29(6):323-336.[32] Giustetto C，Schimpf R，Mazzanti A，et al. Longterm followup of patients with short QT syndrome[J]. J Am Coll Cardiol，2011，58(6):587-595.[33] Smith GL，MacQuaide N.The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action oflocal anesthetics in CPVT[J].Circ Res，2015，116(8):1284-1286.[34] RosesNoguer F，Jarman JW，Clague JR，et al.Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia[J].Heart Rhythm，2014，11(1):58-66.[35] Marcus FI，McKenna WJ，Sherrill D，et al.Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task forcecriteria[J].Circulation，2010，121(13):1533-1541.[36] Huikuri HV，Castellanos A，Myerburg RJ.Sudden death due to cardiac arrhythmias[J]. N Engl J Med，2001，345(20):1473-1482.[37] 陈群曼，李乔华.预激综合征的诊断及治疗原则[J].江苏实用心电学杂志，2013，22(4):708-715.[38] 黄从新，张澍，马长生，等.心房颤动:目前的认识和治疗建议——2012[J].中华心律失常学杂志，2012，16(4):246-289.[39] Camm AJ，Lip GY，De Caterina R，et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESCGuidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J，2012，33(21):2719-2747.[40] January CT，Wann LS，Alpert JS，et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report ofthe American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J].Circulation，2014，130(23):2071-2104.
2015, Vol. 24 
